News & Updates
Filter by Specialty:
Two-drug combo rises to the challenge as 1L Tx for mTNBC
In the primary analysis of the ASCENT-04/KEYNOTE-D19 study, a combination regimen comprising sacituzumab govitecan (SG) and pembrolizumab delivers significant progression-free survival (PFS) benefit in women with previously untreated PD-L1+ advanced triple-negative breast cancer (TNBC).
Two-drug combo rises to the challenge as 1L Tx for mTNBC
02 Jul 2025
Add-on olanzapine prevents RT-induced nausea, vomiting
In patients undergoing abdominal-pelvic radiation therapy (RT), treatment with olanzapine along with an antiemetic medication leads to a substantial decrease in RT-induced nausea and vomiting (RINV), with no serious adverse effects, reports a study presented at ASCO 2025.
Add-on olanzapine prevents RT-induced nausea, vomiting
01 Jul 2025
Novel GLP-1/GIP formula finishes strong in phase II obesity, T2D trial
In part 1 (dose ranging with and without dose escalation) of the phase II MariTide study, significant weight reduction and robust glycaemic improvement were achieved with maridebart cafraglutide (MariTide) – the first, long-acting, GIPR* antagonist and GLP-1R** agonist – in individuals with obesity or overweight and type 2 diabetes (T2D).
